Evidence map›Paper›PMID 24448926›Full record

ReviewStem cells (Dayton, Ohio)2014

Concise review: Stem cell therapies for amyotrophic lateral sclerosis: recent advances and prospects for the future.

J Simon Lunn, Stacey A Sakowski, Eva L Feldman

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Stem cells (Dayton, Ohio), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 4 pooled it
9.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 4 syntheses or guidelines pooled it, 81 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Cell-based therapies for amyotrophic lateral sclerosis/motor neuron disease.The Cochrane database of systematic reviews · 2019
    Pooled it
  4. Cell-based therapies for amyotrophic lateral sclerosis/motor neuron disease.The Cochrane database of systematic reviews · 2016
    Pooled it
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Regenerative Stem Cell Therapy for Neurodegenerative Diseases: An Overview.International journal of molecular sciences · 2021
    Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

J Simon LunnDepartment of Neurology, University of Michigan, Ann Arbor, Michigan, USA.
Stacey A Sakowski
Eva L Feldman
University of Michigan–Ann Arbor · USA. Alfred Taubman Health Care Center · US

Funding

Phase 1b Trial of stem cells in ALSR01NS077982 · NINDS · EMORY UNIVERSITY · PI BOULIS, NICHOLAS M, FELDMAN, EVA LUCILLE · 2012 to 2015
$2.5M
NINDS NIH HHS R01 NS077982
6 · The paper itself

Abstract

Amyotrophic lateral sclerosis (ALS) is a lethal disease involving the loss of motor neurons. Although the mechanisms responsible for motor neuron degeneration in ALS remain elusive, the development of stem cell-based therapies for the treatment of ALS has gained widespread support. Here, we review the types of stem cells being considered for therapeutic applications in ALS, and emphasize recent preclinical advances that provide supportive rationale for clinical translation. We also discuss early trials from around the world translating cellular therapies to ALS patients, and offer important considerations for future clinical trial design. Although clinical translation is still in its infancy, and additional insight into the mechanisms underlying therapeutic efficacy and the establishment of long-term safety are required, these studies represent an important first step toward the development of effective cellular therapies for the treatment of ALS.

Indexed as

Amyotrophic Lateral SclerosisAnimalsBiomedical ResearchCell DifferentiationForecastingHumansModels, NeurologicalMotor NeuronsStem CellsStem Cell TransplantationCell transplantationCellular therapyClinical translationMesenchymal stem cellsNeural stem cellProgenitor cellsStem cell transplantationTransplantation

Identifiers

PMID24448926
PMCPMC4225704
OpenAlexW1613946354

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.